NCT04677361View on ClinicalTrials.gov

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

EARLY_PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2024

Conditions

SCLCNSCLC

Interventions

COMBINATION_PRODUCT

MILs™ in Combination with Pembrolizumab

Efficacy and Safety of MILs™ in Combination with Pembrolizumab in Patients with NSCLC and SCLC

Sponsors

Collaborators (1)

WindMIL Therapeutics

All Listed Sponsors

collaborator

WindMIL Therapeutics

INDUSTRY

lead

Fox Chase Cancer Center

OTHER

NCT04677361 - Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab | Biotech Hunter | Biotech Hunter